Ann: Trading Halt, page-22

I'm just going back through the Atomo news/announcements, and the lead-up seems decent:

1. 23/01/2018 - Atomo Diagnostics and Access Bio partner to expand access to Best-inClass HIV Rapid Testing in Global Markets
2. 15/04/2020 - Atomo receives a second purchase order from NG Biotech
3. 07/05/2020 - Atomo receives an additional order from NG Biotech
4. 04/06/2020 - Atomo and NG Biotech expand COVID-19 partnership (exclusive rights)
5. 28/07/2020 - Atomo Diagnostics and Access Bio partner to expand access to COVID-19 blood-based rapid testing in North America
6. 10/08/2020 - Atomo receives TGA approval for its COVID-19 rapid antibody test
7. 23/09/2020 - DIVOC Labs to sell Atomo's COVID-19 rapid antibody test in India
8. 29/09/2020 - Atomo and Access Bio expand partnership to launch a rapid COVID-19 antigen test in Australia, NZ and India
9. 27/10/2020 - Atomo receives TGA approval for its COVID-19 rapid antigen test
10. 10/10/2020 - Atomo receives TGA approval for its AtomoRapid HIV (1&2) professional use rapid diagnostic test
11. 07/12/2020 - Atomo Provides Update on its HIV Rapid Test Business (includes an agreement with PrEP Health Pty Ltd for distribution)
12. 29/04/2021 - Viatris Inc. and Atomo Diagnostics Announce Agreement with Unitaid to Expand Access to HIV Self-Test
13. 30/04/2021 - Atomo appoints Bondi Partners to advise Atomo's US go-to-market strategy. 4 million unlisted options issued to Bondi Partners at exercise prices of $0.40 and $0.60
14. 28/06/2021 - Access Bio receives FDA clearance for COVID-19 antigody test. This announcement also stated that "Atomo and Access Bio are in discussions regarding their COVID-19 rapid test commercial arrangements and Atomo will keep the market informed as to any material developments."
15. 04/10/2021 - Trading Halt regarding commercial arrangements with Access Bio Inc